BIRMINGHAM, Ala. – Most animal, plant and fungal cells contain organelles called mitochondria. These descendants of a primordial bacterial endosymbiont still preserve distinct genes and are known for their ability to create ATP as chemical energy. They also have other important functions, including cell signaling, viral and bacterial sensing, cell division, cell death, and innate and adaptive immune responses. Consequently, impairment in mitochondrial function can result in aging and age-related diseases.
An emerging area of research is the evolutionarily conserved transfer of mitochondria between cells. Yet researchers have lacked unique and universally accepted terms and practices to describe such transfers. Absent an agreed nomenclature and standard practices, different researchers may use different methods and terminology to describe the same event, or they may employ the same term that actually describe two different processes.
“Over the past few years, we have come to understand that mitochondria can be transferred from one cell to another, and that isolated mitochondria can be transplanted like an organ transplant,” said Keshav K. Singh, Ph.D., professor in the University of Alabama at Birmingham Department of Genetics. “Though the origins of mitochondria transfer are unclear, it has been observed in evolutionarily diverse eukaryotes, including yeast, mollusks, fish and rodents, as well as human cells. We are just beginning to understand how alterations in this process contribute to disease pathogenesis and how to harness mitochondria transfer and transplantation biology to develop new therapies.”
In 2024, Singh and Jonathan Brestoff, M.D., Ph.D., Washington University School of Medicine, Saint Louis, Missouri, set up an international consortium on mitochondria transfer and transplantation and led an international team of 31 researchers to develop consensus and recommendations about how to advance the field by providing common terminology and characterizations for the transfer or transplantation of mitochondria. Their consensus paper, “Recommendations for mitochondria transfer and transplantation nomenclature and characterization,” is published in the journal Nature Metabolism.
The paper begins with a brief history of the field — some foundational early discoveries, recent studies of mitochondrial transfer and development of therapeutic approaches, including cell engineering and clinical trials for children requiring extracorporeal membrane oxygenation.
The paper defines types of mitochondria transfer and mitochondria transplantation, and when both the donor and acceptor cell types are established in vivo, that defines a mitochondria transfer axis. The paper reviews methods to define mitochondria transfer, including mitochondria reporter proteins and dyes, methods to enforce transfer, and discussion of the fate of mitochondria after cell entry. Mechanism-based nomenclature is roughly grouped into contact-dependent mitochondria transfer, where the donor cell and recipient cell touch each other, and contact-independent mitochondria transfer.
The recommendations also review therapeutic approaches of mitochondria transplantation, including the definition of transplants; the types, durability, degree of engraftment and heterogeneity of transplants; cell engineering using extracellular mitochondria; and drugs that affect mitochondria transfer. Extracellular mitochondria are common in humans — for example there are about 3 billion to 12 billion extracellular mitochondria in a unit of blood platelets, a blood product that is routinely and safely transfused to patients intravenously.
The paper concludes that “the goal of this proposed nomenclature is to reduce the confusion that can be caused by the introduction of different names for similar processes or extracellular mitochondria subsets as this field has evolved. We recognize that mitochondria transfer and transplantation are very active areas of research and that it is possible that new findings and insights may necessitate updates to the proposed nomenclature.”
Singh has a long-standing interest in mitochondria. He was founding editor-in-chief of the journal Mitochondrion and the founder of the Society for Mitochondria Research and Medicine. In 2007 and 2009, his laboratory showed that isolated mouse mitochondria can be transferred to human cells by co-incubation, providing a proof of principle for transfer of mitochondria by diffusion, and that xeno-transplanted platelet mitochondria from an African American woman who suffered aggressive breast cancer at young age was able to recapitulate aggressiveness of breast cancer in mice. At that time, these findings were not appreciated by the field, Singh says.
Along with corresponding authors Singh and Bresthoff, 29 other researchers are co-authors of the Nature Metabolism paper.
At UAB, Genetics is a department in the Marnix E. Heersink School of Medicine.
Journal
Nature Metabolism
Method of Research
Systematic review
Subject of Research
Not applicable
Article Title
Recommendations for mitochondria transfer and transplantation nomenclature and characterization
Article Publication Date
16-Jan-2025
COI Statement
Jonathan R. Brestoff, Keshav K. Singh, Eric Boilard, Lance B. Becke,r Andrés Caicedo, José Antonio Enríquez, Åsa B. Gustafsson, Maroun Khoury, Ritsuko Nakai, Alexander J. Sercel, Michael A. Teitell, Alain R. Thierry, Rong Tian, and Melanie Walker have competing interests. J.R.B. is a member of the Scientific Advisory Board of LUCA Science, Inc.; receives research support from LUCA Science and Edgewise Therapeutics; is a consultant for Columbus Instruments, Inc.; has consulted for DeciBio within the past 12 months; receives royalties from Springer Nature Group; is an inventor on technology licensed to Columbus Instruments, Inc. with royalty rights; and is an inventor on pending patent applications related to the treatment of metabolic diseases (63/625,555) and allergic diseases (US20210128689A1) and mitochondria transfer (018984/US). K.K.S. is a co-founder, holds equity in, and serves on the Scientific Advisory Board for YUVA Biosciences. E.B. holds patents on detection of extracellular mitochondria in inflammatory conditions (WO2015051466A1) and on mitochondrial autoantibodies in autoimmune diseases (WO2022/246565A1), and is a principal investigator and scientific advisor to MitrixBio. L.B. receives grant support from Philips Medical Systems, ZOLL Medical Corp, Nihon Kohden, PCORI, BrainCool and United Therapeutics; is on the Scientific Advisory Board for Nihon Kohden, HP and Philips; holds seven issued patents and several pending patent applications involving the use of medical slurries as human coolant devices, the creation of slurries, reperfusion cocktails, and measurement of respiratory quotient; and serves on committees for the American Heart Association, which has a financial interest in the outcome of resuscitation studies being conducted and that sells training materials worldwide on resuscitation techniques. A.C. is a founder of and scientific advisor to Dragon Biomed and a scientific advisor to Luvigix. J.A.E. has collaborated with Minova Therapeutics. A.B.G. is a consultant for Lexeo Therapeutics. J.D.M. has pending patents for the isolation and use of isolated mitochondria and is a founder and member of the Scientific Advisory Board and Board of Directors for cellvie. M.K. is the chief scientific officer of Cells for Cells, EVast Bio, and Regenero (Chilean consortium for regenerative medicine) with Corporacion de Fomento de la Produccion support; has received research support from ANID (National Agency for Research and Development) basal FB210024 and Cells for Cells; is an inventor on patents related to mesenchymal stem cells (pending patents WO2014135924A1, WO20170646770A2, WO2017064672A1 and WO2019051623). R.N. receives research support from LUCA Science, Inc. A.J.S. is an employee of Mitochondria World. M.A.T. is a co-founder and shareholder for NanoCav, a private start-up company with licenses for mitochondria-transfer techniques and applications. A.R.T. is an inventor of a pending patent related to the diagnostic detection of cf-mtDNA (WO 2016/063122 A1). R.T. is a scientific advisor for Cytokinetics, Inc. and GenKardia, Inc. M.W. has a pending patent (US20210085713A1) related to compositions and methods for treating stroke.